ArticleThe European respiratory journal2024
Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Breathing insights: Biomarkers as tools for chronic obstructive pulmonary disease assessment - A systematic review.Indian journal of pharmacology · 2026Pooled it
- Biological age acceleration and cardiovascular-kidney-metabolic syndrome progression: evidence from UK Biobank and NHANES.Renal failure · 2026Article
- Liver-specific phenotypic aging, behavior and genetic risks, and long-term liver-related outcomes.GeroScience · 2026Article
- Healthy diet and slower biological aging as protective factors against microvascular complications in type 2 diabetes.GeroScience · 2026Article
- Cross-Sectional and Longitudinal Association Between Biological Aging Acceleration and the Risk of Osteoarthritis: A Cohort Study From UK Biobank.International journal of rheumatic diseases · 2026Article
- Integrating biological aging into clinical practice: a review and path forward for precision longevity medicine.GeroScience · 2026Review
- Phenotypic age acceleration and genetic risk synergistically increase age-related eye disease risk in the UK Biobank.Scientific reports · 2026Article
- Phenotypic age acceleration as a novel predictor of benign prostatic hyperplasia: a prospective cohort study.GeroScience · 2026Article
- Biological age acceleration, genetic susceptibility, and incident diabetic retinopathy risk: A prospective cohort study.The journal of nutrition, health & aging · 2026Article
- Accelerated biological aging and underlying epigenetic modification mediated the association between obesity and asthma.Clinical epigenetics · 2026Article
- Phenotypic age acceleration: a novel biomarker associated with increased risk of metabolic dysfunction-associated fatty liver disease.Nutrition & metabolism · 2026Article
- Association between frailty and the risks of chronic pulmonary diseases and lung cancer.BMC pulmonary medicine · 2026Article
- Deep Learning-Based Estimated Pulmonary Biological Age From Chest Computed Tomography Images in Healthy Adults: Model Development and Validation Study.JMIR aging · 2026Article
- Gut microbiota dysbiosis and metabolic abnormalities promote oxidative stress and fibrosis in idiopathic pulmonary fibrosis.Scientific reports · 2026Article
- Association between cardiovascular-kidney-metabolic syndrome and chronic obstructive pulmonary disease: a cross-national analysis from global, US, and Chinese populations.Respiratory research · 2026Article
- PhenoAge and PhenoAgeAccel do not outperform chronological age in predicting physical performance decline or mortality in community-dwelling older adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Biological age acceleration and interaction with genetic predisposition in the risk of type 2 diabetes and coronary artery disease.GeroScience · 2026Article
- Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities.Nature reviews. Drug discovery · 2026Review
- Phenotypic age acceleration and omega-6/omega-3 PUFA ratio in dynamic atrial fibrillation-heart failure transitions: a multistate analysis.The journal of nutrition, health & aging · 2026Article
- Distinct comorbidity profiles and outcomes in asbestosis versus idiopathic pulmonary fibrosis: a 6-year prospective cohort study.BMC pulmonary medicine · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccelerated biological ageing has been associated with an increased risk of several chronic respiratory diseases. However, the associations between phenotypic age, a new biological age indicator based on clinical chemistry biomarkers, and common chronic respiratory diseases have not been evaluated.
methodsWe analysed data from 308 592 participants at baseline in the UK Biobank. The phenotypic age was calculated from chronological age and nine clinical chemistry biomarkers, including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percent, mean cell volume, red cell distribution width and white blood cell count. Furthermore, phenotypic age acceleration (PhenoAgeAccel) was calculated by regressing phenotypic age on chronological age. The associations of PhenoAgeAccel with incident common chronic respiratory diseases and cross-sectional lung function were investigated. Moreover, we constructed polygenic risk scores and evaluated whether PhenoAgeAccel modified the effect of genetic susceptibility on chronic respiratory diseases and lung function.
resultsThe results showed significant associations of PhenoAgeAccel with increased risk of idiopathic pulmonary fibrosis (IPF) (hazard ratio (HR) 1.52, 95% CI 1.45-1.59), COPD (HR 1.54, 95% CI 1.51-1.57) and asthma (HR 1.18, 95% CI 1.15-1.20) per 5-year increase and decreased lung function. There was an additive interaction between PhenoAgeAccel and the genetic risk for IPF and COPD. Participants with high genetic risk and who were biologically older had the highest risk of incident IPF (HR 5.24, 95% CI 3.91-7.02), COPD (HR 2.99, 95% CI 2.66-3.36) and asthma (HR 2.07, 95% CI 1.86-2.31). Mediation analysis indicated that PhenoAgeAccel could mediate 10∼20% of the associations between smoking and chronic respiratory diseases, while ∼10% of the associations between particulate matter with aerodynamic diameter <2.5 µm and the disorders were mediated by PhenoAgeAccel.
conclusionPhenoAgeAccel was significantly associated with incident risk of common chronic respiratory diseases and decreased lung function and could serve as a novel clinical biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.